StayCurrentMD · Displacement of Bilirubin from Albumin by Omegaven and Intralipid
Article1 min read·Published Sep 2025

Displacement of Bilirubin from Albumin by Omegaven and Intralipid

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Sep 2025 · 1 min read

In brief

In brief

This study compares two lipid emulsions used in neonatal parenteral nutrition—soybean oil-based Intralipid and fish oil-based Omegaven—focusing on their potential to displace bilirubin from albumin. Understanding this displacement mechanism is critical for preventing bilirubin-induced neurologic dysfunction in vulnerable neonates receiving intravenous nutrition.

  • Intralipid increases unbound free fatty acids, which displace bilirubin from albumin and raise BIND risk in neonates.
  • Omegaven (fish oil-based lipid) offers hepatoprotective benefits but its bilirubin displacement profile requires further study.
  • Clinicians should monitor bilirubin levels closely when using lipid emulsions in jaundiced neonates on parenteral nutrition.

Written by the GCMD Library team from the article.

Intralipid, a soybean oil-based fat emulsion, is the only FDA-approved lipid source for neonatal parenteral nutrition, but it increases unbound free fatty acids (FFAu), which can displace bilirubin from albumin and elevate the risk of bilirubin-induced neurologic dysfunction (BIND). Omegaven, a fish oil-based alternative, exhibits hepatoprotective properties; however, its effect on bilirubin displacement is less well understood.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →